58 related articles for article (PubMed ID: 24649861)
1. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
Mehta N; Dodge JL; Roberts JP; Yao FY
J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.
Samoylova ML; Dodge JL; Mehta N; Yao FY; Roberts JP
Clin Transplant; 2015 Jan; 29(1):52-9. PubMed ID: 25366656
[TBL] [Abstract][Full Text] [Related]
3. Women Are Also Disadvantaged in Accessing Transplant Outside the United States: Analysis of the Spanish Liver Transplantation Registry.
Tejedor M; Neria F; De La Rosa G; Almohalla Álvarez C; Padilla M; Boscà Robledo A; Fundora Suárez Y; Sánchez-Bueno F; Gómez-Bravo MA; Berenguer M
Transpl Int; 2024; 37():12732. PubMed ID: 38773987
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal analysis of liver transplant candidates for hepatocellular carcinoma in a single center.
Ho CM; Lee PH; Cheng HY; Hsaio CY; Wu YM; Ho MC; Hu RH
Langenbecks Arch Surg; 2024 Apr; 409(1):143. PubMed ID: 38683375
[TBL] [Abstract][Full Text] [Related]
5. Superiority of the new sex-adjusted models to remove the female disadvantage restoring equity in liver transplant allocation.
Marrone G; Giannelli V; Agnes S; Avolio AW; Baiocchi L; Berardi G; Ettorre GM; Ferri F; Corradini SG; Grieco A; Guglielmo N; Lenci I; Lionetti R; Mennini G; Milana M; Rossi M; Spoletini G; Tisone G; Manzia TM; Lai Q
Liver Int; 2024 Jan; 44(1):103-112. PubMed ID: 37752798
[TBL] [Abstract][Full Text] [Related]
6. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?
Hu X; Chen R; Wei Q; Xu X
Int J Biol Sci; 2022; 18(2):536-551. PubMed ID: 35002508
[TBL] [Abstract][Full Text] [Related]
7. Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology.
McVey JC; Sasaki K; Firl DJ
Hepat Oncol; 2020 Jul; 7(3):HEP26. PubMed ID: 32774836
[TBL] [Abstract][Full Text] [Related]
8. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria.
Amado V; Rodríguez-Perálvarez M; Ferrín G; De la Mata M
J Hepatocell Carcinoma; 2019; 6():1-10. PubMed ID: 30613572
[TBL] [Abstract][Full Text] [Related]
9. Selection of patients with hepatocellular cancer: a difficult balancing between equity, utility, and benefit.
Vitale A; Lai Q
Transl Gastroenterol Hepatol; 2017; 2():75. PubMed ID: 29034348
[TBL] [Abstract][Full Text] [Related]
10. Liver-allocation policies for patients affected by HCC in Europe.
De Carlis L; Di Sandro S; Centonze L; Lauterio A; Buscemi V; De Carlis R; Ferla F; Sguinzi R; Okolicsanyi S; Belli L; Strazzabosco M
Curr Transplant Rep; 2016 Dec; 3(4):313-318. PubMed ID: 28473952
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry.
Alver SK; Lorenz DJ; Washburn K; Marvin MR; Brock GN
Transpl Int; 2017 Nov; 30(11):1098-1109. PubMed ID: 28403575
[TBL] [Abstract][Full Text] [Related]
12. HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations?
Strassburg CP
Visc Med; 2016 Aug; 32(4):263-271. PubMed ID: 27722163
[TBL] [Abstract][Full Text] [Related]
13. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future.
Soriano A; Varona A; Gianchandani R; Moneva ME; Arranz J; Gonzalez A; Barrera M
World J Hepatol; 2016 Jan; 8(1):58-68. PubMed ID: 26783421
[TBL] [Abstract][Full Text] [Related]
14. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
[TBL] [Abstract][Full Text] [Related]
15. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
[TBL] [Abstract][Full Text] [Related]
16. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
[TBL] [Abstract][Full Text] [Related]
17. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
[TBL] [Abstract][Full Text] [Related]
18. Model for End Stage Liver Disease and hepatocellular carcinoma: a moving target.
Washburn K
Transplant Rev (Orlando); 2010 Jan; 24(1):11-7. PubMed ID: 19942101
[TBL] [Abstract][Full Text] [Related]
19. Current controversies surrounding liver transplantation for hepatocellular carcinoma.
Silva MF; Wigg AJ
J Gastroenterol Hepatol; 2010 Jul; 25(7):1217-26. PubMed ID: 20594247
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
